Chenlong Liao

Dr. Chenlong Liao

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2019
Verified
Book Chapter
Closed access
PDF file
CLChenlong Liao
Chenlong Liao
MVMassimiliano Visocchi
Massimiliano Visocchi
WZWenchuan Zhang
Wenchuan Zhang
SLShiting Li
Shiting Li
MYMin Yang
Min Yang
PLPengfei Liu
Pengfei Liu

21 February 2025 in Chemical Engineering Journal
Verified
Journal Article
Closed access
JSJiahui Song
Jiahui Song
SWSiyuan Wu
Siyuan Wu
CLChenlong Liao
Chenlong Liao
ZYZhengchao Yuan
Zhengchao Yuan
XYXiao Yu
Xiao Yu
Xiumei MoXiumei Mo
Xiumei Mo

1 July 2016 in World Neurosurgery
Verified
Journal Article
Closed access
CLChenlong Liao
Chenlong Liao
WZWenchuan Zhang
Wenchuan Zhang
MYMin Yang
Min Yang
WZWenxiang Zhong
Wenxiang Zhong
PLPengfei Liu
Pengfei Liu
SLShiting Li
Shiting Li

7 March 2025 in Cells
Verified
Journal Article
Open access
PDF file
Xin XuXin Xu
Xin Xu
YZYue Zhang
Yue Zhang
SLShuo Li
Shuo Li
CLChenlong Liao
Chenlong Liao
YXYang Xiaosheng
Yang Xiaosheng
WZWenchuan Zhang
Wenchuan Zhang
Diabetic peripheral neuropathy (DPN) is a prevalent and disabling complication of diabetes, with painful diabetic peripheral neuropathy (PDPN) being its most severe subtype due to chronic pain and resistance to treatment. Satellite glial cells (SGCs), critical for maintaining dorsal root ganglion (DRG) homeostasis, undergo significant structural and functional changes under pathological conditions. This study investigated the role of galactosylceramide (GalCer), a key sphingolipid, in SGC dysfunction and neuron–glia interactions during DPN progression. Using a rat model of PDPN, we employed single-cell RNA sequencing (scRNA-seq), targeted mass spectrometry, and immunofluorescence analysis. The PDPN group exhibited transcriptional activation and structural reorganization of SGCs, characterized by increased SGC abundance and glial activation, evidenced by elevated Gfap expression. Functional enrichment analyses revealed disruptions in sphingolipid metabolism, including marked reductions in GalCer levels. Subclustering identified vulnerable SGC subsets, such as Cluster a, with dysregulated lipid metabolism. The depletion of GalCer impaired SGC-neuron communication, destabilizing DRG homeostasis and amplifying neurodegeneration and neuropathic pain. These findings demonstrate that GalCer depletion is a central mediator of SGC dysfunction in PDPN, disrupting neuron–glia interactions and exacerbating neuropathic pain. This study provides novel insights into the molecular mechanisms of DPN progression and identifies GalCer metabolism as a potential therapeutic target.

8 May 2024 in European Radiology
Verified
Journal Article
Closed access
PDF file
SLShuo Li
Shuo Li
HCHongjin Chen
Hongjin Chen
JCJiahao Chen
Jiahao Chen
XYXiaosheng Yang
Xiaosheng Yang
WZWeijie Zhong
Weijie Zhong
WZWenchuan Zhang
Wenchuan Zhang

1 January 2024 in Therapeutic Advances in Neurological Disorders
Verified
Journal Article
Open access
CLChenlong Liao
Chenlong Liao
WZWenchuan Zhang
Wenchuan Zhang
Diabetic peripheral neuropathy (DPN) is one of the most common complications of diabetes which primarily affects the sensory nervous system. Pain is the most common complaint that prompts patients to seek medical advice. With various presentations and intricate pathological mechanisms, diabetic peripheral neuropathic pain is currently the most crucial and challenging aspect of managing diabetic complications. As a heterogeneous disorder, there is no medication or treatment modality that is effective for all types of DPN and its associated neuropathic pain. Peripheral nerve decompression provides a new option for treating patients with diabetic peripheral neuropathic pain in the lower extremities. However, the clinical applicability of nerve decompression has been debated since it was first proposed. This review discusses the theoretical basis of nerve decompression, the clinical indications, and the progress of basic research based on the pathological mechanisms and nerve impairment patterns of diabetic peripheral neuropathic pain. The heterogeneity of DPN patients is summarized in terms of three aspects: complex pathophysiological mechanisms, multilevel nervous system involvement, and various nerve impairment properties. Identifying the presence of nerve entrapment among complex pathophysiological mechanisms is the key to successful outcomes. Tinel signs, focal pain, mechanical allodynia, and two-point discrimination were reported to be prognostic factors for good surgical outcomes, and their predictive ability might stem from their association with the early stage of entrapment neuropathy.